Trials
3 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NEO100 is a purified form (\>98.5%) of the naturally occurring monoterpene perillyl alcohol. NEO100 drug product is a non-sterile solution for intranasal administration. It is compounded as a 10% solution in a 50:50 mixture of ethanol:glycerol.”In the company’s words, NCT06357377 on ClinicalTrials.gov
- Tested for
- Residual, Progressive or Recurrent Grade II or III Meningioma, Glioblastoma Multiforme, Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood and 2 more
- Main trialPhase 2
- “This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study…”In the company’s words, NCT05023018 on ClinicalTrials.gov
- Other names
- Perillyl alcohol
Other drugs for Residual, Progressive or Recurrent Grade II or III Meningioma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TazemetostatEpizyme, Inc. · Phase 3
- EpcoritamabGenmab · Phase 3
- OdronextamabRegeneron · Phase 3
- SurovatamigAstraZeneca · Phase 3
- GolcadomideCelgene · Phase 3
Coming up3
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Dec 2026 | NEO100 and High-Grade Meningioma | |
| Phase 1/2Active, not recruiting | 30 Nov 2026 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | |
| Phase 1Recruiting | Jun 2027 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026